Suritozole

Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABA_A ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM.[1] It was investigated for the treatment of depression and Alzheimer's disease,[2] but clinical development seems to have been discontinued.

Suritozole

Clinical data
ATC code	none
Identifiers
IUPAC name 5-(3-fluorophenyl)-2,4-dimethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
CAS Number	110623-33-1
PubChem CID	25431
ChemSpider	23743
UNII	3H7H68317X
KEGG	D05980
CompTox Dashboard (EPA)	DTXSID10149333
Chemical and physical data
Formula	C10H10FN3S
Molar mass	223.27 g·mol^−1
3D model (JSmol)	Interactive image
SMILES Cn1c(=S)n(C)nc1-c2cccc(F)c2
InChI InChI=1S/C10H10FN3S/c1-13-9(12-14(2)10(13)15)7-4-3-5-8(11)6-7/h3-6H,1-2H3 Key:IWDUZEHNLHFBRZ-UHFFFAOYSA-N
(what is this?)  (verify)

See also

• GABA_A receptor negative allosteric modulator
• GABA_A receptor § Ligands

References

1. Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM (September 1992). "MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties". Br. J. Pharmacol. 107 (1): 78–86. doi:10.1111/j.1476-5381.1992.tb14466.x. PMC 1907590. PMID 1330168.
2. Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ (May 1997). "Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers". Biopharm Drug Dispos. 18 (4): 325–34. doi:10.1002/(SICI)1099-081X(199705)18:4<325::AID-BDD21>3.0.CO;2-1. PMID 9158880.